Back to Journals » Cancer Management and Research » Volume 12

Associations Between miRNAs and Two Different Cancers: Breast and Colon

Authors Kundaktepe BP, Sozer V, Papila C, Durmus S, Kocael PC, Simsek G, Gelisgen R, Zengin K, Ulualp K, Uzun H

Received 17 August 2019

Accepted for publication 22 January 2020

Published 7 February 2020 Volume 2020:12 Pages 871—879

DOI https://doi.org/10.2147/CMAR.S227628

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Berrin Papila Kundaktepe,1 Volkan Sozer,2 Cigdem Papila,3 Sinem Durmus,4 Pinar Cigdem Kocael,1 Gonul Simsek,5 Remise Gelisgen,4 Kagan Zengin,1 Kenan Ulualp,1 Hafize Uzun4

1Department of General Surgery, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 2Department of Biochemistry, Yildiz Technical University, Istanbul, Turkey; 3Department of Internal Medicine, Division of Oncology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 4Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 5Department of Physiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

Correspondence: Hafize Uzun
Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Cerrahpasa, İstanbul 34303, Turkey
Tel +90 212 414 30 56
Fax +90 212 633 29 87
Email huzun59@hotmail.com

Objective: Screening approaches using microRNAs (miRNAs) have been gaining increased attention owing to their potential applications in the diagnosis, prognosis, and monitoring of cancer, because aberrant miRNA expression plays a role in the development and advancement of malignancies. The objectives of this study were to characterize mir21, miR31, mir143, mir145, and control RNU43, which are differentially expressed in peripheral blood mononuclear cells (PBMCs) of breast and colorectal cancer patients, compared to that in controls and to establish whether this is specific to breast and colon cancer for use as tumor markers.
Methods: Thirty newly diagnosed patients with breast cancer and 30 patients with colorectal cancer were enrolled together with 30 healthy controls. PBMCs were isolated from venous blood samples of individuals. Next, miRNA expression analysis was performed by a two-step method of reverse transcription and qPCR.
Results: The expression levels of miR-143 and miR-31 were significantly decreased, whereas the expression levels of miR-145 and miR-21 were significantly increased in breast cancer patients compared to those in healthy subjects. Moreover, the expression levels of miR-143, miR-145, and miR-21 were significantly increased and, in contrast, the changes in the expression levels of miR-31 were not statistically significant in colon cancer compared to those in healthy subjects. miR-21 exhibited the highest increase in both breast and colon cancers. There was a weak positive correlation between miR-145 and CA-15.3 in patients with breast cancer (r = 0.451; p = 0.012). miR-143 was positively correlated with the TNM stage in colon cancer patients (r = 0.568; p = 0.001).
Conclusion: A biomarker panel composed of miR-21, miR-31, miR-143, and miR-145 in PBMC may provide a new diagnostic approach for the early detection of breast and colon cancer. As miR-21 expression was found to be the highest among all the miRNAs evaluated, it may represent a new tumor biomarker and a candidate therapeutic drug or gene target in colon and breast cancer.

Keywords: breast cancer, colon cancer, peripheral blood mononuclear cells, mir21, mir31, mir143, mir145

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]